Published in Acta Haematol Pol on January 29, 1977
Two autologous transplants in the treatment of patients with Hodgkin's lymphoma: analysis of prognostic factors and comparison with a single procedure. Leuk Lymphoma (2007) 1.11
Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant (2005) 0.95
2-chlorodeoxyadenosine (cladribine) in the treatment of hairy cell leukemia and hairy cell leukemia variant: 7-year experience in Poland. Eur J Haematol (1999) 0.86
Outcome of treatment in adults with Philadelphia chromosome-positive and/or BCR-ABL--positive acute lymphoblastic leukemia-retrospective analysis of Polish Adult Leukemia Group (PALG). Ann Hematol (2006) 0.84
Acute lymphoblastic leukemia in elderly: the Polish Adult Leukemia Group (PALG) experience. Ann Hematol (2003) 0.83
2-chlorodeoxyadenosine (2-CdA) in 2-hour versus 24-hour intravenous infusion in the treatment of patients with hairy cell leukemia. Leuk Lymphoma (1996) 0.78
CD-15 antigen detected by the VIM-D5 monoclonal antibody for prediction of ability to achieve complete remission in acute nonlymphocytic leukemia. Acta Haematol (1986) 0.77
Low-dose zinc administration as an effective Wilson's disease treatment. Biol Trace Elem Res (2001) 0.76
Cooperative randomized studies on the treatment of adult acute leukemia in Poland. A comparison of two remission induction regimes and two maintenance regimes for AML. Folia Haematol Int Mag Klin Morphol Blutforsch (1984) 0.75
[Use of human recombinant granulopoietic colony growth factor rhGM-CSF combined with interferon alpha for preparation in preparation of a patient with hairy-cell leukemia for splenectomy]. Pol Tyg Lek (1996) 0.75
Expression of cell differentiation antigens as a prognostic factor in acute leukemia. Haematol Blood Transfus (1989) 0.75
Studies on receptor for mouse erythrocytes in lymphocytes of patients with malignant lymphoma. Arch Immunol Ther Exp (Warsz) (1979) 0.75
Rituximab (Mabthera, Rituxan) in patients with recurrent indolent lymphoma: evaluation of safety and efficacy in a multicenter study. Med Oncol (2001) 0.75
[Level of erythropoietin during autologous transplantation of stem cells from bone marrow and peripheral blood]. Acta Haematol Pol (1995) 0.75
High-dose chemotherapy with autologous stem cell transplantation is an effective treatment of primary refractory Hodgkin's disease. Retrospective study of the Polish Lymphoma Research Group. Bone Marrow Transplant (2002) 0.75
[Coexistence of myeloblastic leukemia and miliary tuberculosis; diagnostic and therapeutic difficulties]. Pol Tyg Lek (1984) 0.75
[Cure of tetraplegia caused by metastasis of inoperable breast cancer to the spine]. Przegl Lek (1984) 0.75
Sonography in the diagnosis and therapy monitoring of lymphomas. Neoplasma (1992) 0.75
Expression of CD-15 antigen on leukemic cells--a new prognostic factor for ability to achieve complete remission and for survival in ANLL. Haematol Blood Transfus (1987) 0.75
Embolisation of the splenic artery as an alternative to splenectomy for treating hereditary spherocytosis. Folia Haematol Int Mag Klin Morphol Blutforsch (1983) 0.75
[Effect of toxic factors on the incidence of hematopoietic system damage]. Pol Arch Med Wewn (1981) 0.75
[Prognostic usefulness of certain defined indicators for achieving complete remission and survival of ANLL in adults: proposal of a prognostic scale]. Pol Tyg Lek (1991) 0.75
[A favorable result of immunosuppressive therapy combined with the use of cyclosporine in a case of particularly severe Wegener's granuloma]. Pol Tyg Lek (1995) 0.75
[Syndrome of chronic intravascular coagulation in the course of chronic myeloid leukemia]. Wiad Lek (1994) 0.75
[Primary forms of extralymphatic non-Hodgkin's lymphoma]. Pol Tyg Lek (1996) 0.75
[Goiter as the first symptom of Hodgkin's disease]. Pol Tyg Lek (1984) 0.75
[Change of immunologic phenotype in an atypical case of prolymphocytic leukemia--role of interferon alpha]. Pol Tyg Lek (1995) 0.75
Post-transplant induction of donor-type anti-RhD antibodies production shortly followed by complete hemolysis of recipient-type erythrocytes in RhD-mismatched allogeneic bone marrow recipient. Bone Marrow Transplant (2006) 0.75
[Preliminary results of the treatment of acute leukemia with mitoxantrone]. Acta Haematol Pol (1991) 0.75
Lymphoblastic lymphoma in a female with chronic granulocytic leukaemia. Folia Haematol Int Mag Klin Morphol Blutforsch (1985) 0.75
[Hemophilia A in a woman with gonadal dysgenesia and 46, XX karyotype]. Wiad Lek (1982) 0.75
[Human recombinant alfa-2 interferon in the treatment of hairy cell leukemia]. Acta Haematol Pol (1989) 0.75
[Specificity of the immunofluorescence method for the detection of native membrane immunoglobulins of B lymphocytes]. Pol Tyg Lek (1984) 0.75
The monitoring of lymphocyte subpopulations in non Hodgkin lymphoma patients during chemotherapy. Arch Immunol Ther Exp (Warsz) (1978) 0.75
Cladribine combined with cyclophosphamide and mitoxantrone as front-line therapy in chronic lymphocytic leukemia. Leukemia (2001) 0.75
[Effect of hydrochlorothiazide on various parameters of calcium and phosphate metabolism in patients with increased bone resorption caused by malignant metastases to the skeleton]. Pol Tyg Lek (1979) 0.75
Immunomagnetic method of CD34(+) cell separation. Transplant Proc (1996) 0.75
[The presence of CALLA (common acute lymphoblastic leukemia antigens) and B-cell differentiation antigens in lymphocytic lymphoma]. Pol Tyg Lek (1984) 0.75
[Pancytopenia as a complication of the treatment of toxoplasmosis]. Pol Tyg Lek (1992) 0.75
Lymphocyte subpopulations bearing different surface markers in non-Hodgkin lymphoma. Arch Immunol Ther Exp (Warsz) (1978) 0.75
[3 cases of acute leukemia after radiotherapy]. Pol Tyg Lek (1981) 0.75
[Transformation of type T lymphoma into type B lymphoma]. Acta Haematol Pol (1982) 0.75
[Acute thrombopenic purpura after the administration of Polopirin]. Pol Tyg Lek (1985) 0.75
[Late results of BCG immunotherapy of myelocytic leukemia]. Pol Arch Med Wewn (1983) 0.75
[Techniques of positive isolation of CD34(+) cells. Personal experience with the immunomagnetic method]. Acta Haematol Pol (1996) 0.75
Application of a combined rosette-fluorescent test in studies on leukemia cells. Arch Immunol Ther Exp (Warsz) (1979) 0.75
[Pancytopenia and immunologic disorders in Weber-Christian disease]. Pol Tyg Lek (1984) 0.75
[Evaluation of lymphocyte subpopulations during the remission-maintaining treatment of patients with myeloblastic leukemia]. Acta Haematol Pol (1988) 0.75
[Excretion of beta-2-microglobulin and Tamm-Horsfall protein in patients undergoing a conditioning regimen before bone marrow transplantation]. Pol Arch Med Wewn (1994) 0.75
[Classification of acute leukemias--controversy and need for constant updating]. Pol Tyg Lek (1993) 0.75
[Malignant external otitis: a rare complication after autologous bone marrow transplantation]. Wiad Lek (2000) 0.75
[Significance of the detection of antinuclear antibodies and antibodies against native DNA in autoimmune hemolytic anemia]. Pol Tyg Lek (1988) 0.75
[Rehabilitation exercises as a method of preventing polyneuropathies after vincristine treatment]. Acta Haematol Pol (1985) 0.75
[Combined cytostatic treatment of non-Hodgkin's malignant lymphoma]. Pol Tyg Lek (1979) 0.75
[Proposal of a standard set of monoclonal antibodies for differential diagnosis of acute nonlymphocytic leukemia]. Pol Tyg Lek (1993) 0.75
[Hemolytic anemia caused by excessive use of analgesics]. Wiad Lek (1992) 0.75
[Chromosomal disorders in acute human leukemias]. Pol Tyg Lek (1995) 0.75
[Thrombocythemia in a patient after bone marrow autotransplantation with the use of human recombinant granulocyte-monocyte colony growth factor]. Pol Tyg Lek (1995) 0.75
Unrelated donor bone marrow transplantation with treosulfan-based myeloablative conditioning for paroxysmal nocturnal hemoglobinuria--successful treatment despite multiple transplant-related risk factors for hemolysis including major Kidd group incompatibility. Bone Marrow Transplant (2006) 0.75
Electrophoretic mobility of leukocytes in leukemia patients. Arch Immunol Ther Exp (Warsz) (1984) 0.75
[Comparison of clinical usefulness of immunophenotyping of leukemia using the immunofluorescence and immunoenzyme APAAP methods]. Acta Haematol Pol (1992) 0.75
[Methods increasing the specificity of detecting native surface immunoglobulins of B lymphocytes]. Pol Arch Med Wewn (1984) 0.75
[Stages of B-lymphocyte differentiation in acute lymphoblastic leukemia]. Pol Tyg Lek (1991) 0.75
Clinical studies on aclacinomycin A cardiotoxicity in adult patients with acute non lymphoblastic leukaemia. Folia Haematol Int Mag Klin Morphol Blutforsch (1989) 0.75
Haemocompatibility of extracorporeal circulation technique with autooxygenation: influence on platelet function and homologous blood requirement. Folia Haematol Int Mag Klin Morphol Blutforsch (1990) 0.75
Parallel examination of receptors of malignant lymphoma cells using combined tests with mouse erythrocytes and monoclonal VIB-C5 antibody or polyvalent serum against human immunoglobulins. Arch Immunol Ther Exp (Warsz) (1984) 0.75
[Central nervous system relapses in acute lymphoblastic leukemia and different methods of prophylaxis]. Acta Haematol Pol (1995) 0.75
Fractional administration of adriblastin and modified route of ara-C administration for the treatment of acute leukaemia. Folia Haematol Int Mag Klin Morphol Blutforsch (1985) 0.75
[Myeloblastic leukemia in IgG lambda multiple myeloma]. Pol Tyg Lek (1986) 0.75
Acid phosphatase activity of the lymphocytes during polychemotherapy of lymphoproliferative diseases. Arch Immunol Ther Exp (Warsz) (1981) 0.75
Electrophoretic mobility of blood lymphocytes stored at -196 degrees. Arch Immunol Ther Exp (Warsz) (1984) 0.75
Studies on the activity of selected lysosomal exoglycosidases in patients with systemic lupus erythematosus. Med Interne (1984) 0.75
Correlation between the rosette test with neuraminidase-treated sheep red blood cells and acid phosphatase activity in lymphocytes from patients with lymphoproliferative disease. Arch Immunol Ther Exp (Warsz) (1979) 0.75
[The effect of short-term erythropoietin therapy on selected parameters of cell mediated and humoral immunity in hemodialyzed uremic patients]. Pol Arch Med Wewn (1995) 0.75
Autologous bone marrow transplantation in adult acute lymphoblastic leukaemia. Transplant Proc (1996) 0.75
[Clinical and immunological characteristics of prolymphocytic leukemia]. Pol Tyg Lek (1984) 0.75
[Immunological characteristics of plasmacytic leukemia]. Pol Tyg Lek (1984) 0.75
Application of series of monoclonal antibodies against human white cell differentiation antigens and the common ALL antigen in the characterization of leukemia cells. Arch Immunol Ther Exp (Warsz) (1984) 0.75
Creatine in red cells of patients with haematological diseases. Mater Med Pol (1979) 0.75
[Evaluation of the myelogram carried out on the 6th day of remission- inducing treatment of acute nonlymphoblastic leukemia in adults as an indicator of therapeutic effectiveness]. Pol Tyg Lek (1991) 0.75
[Cell membrane antigens in hairy cell leukemia]. Pol Tyg Lek (1984) 0.75
Allogeneic transplantation of selected peripheral CD34+ cells with controlled CD3+ cells add-back in high-risk patients. Transplant Proc (2004) 0.75
Terminal deoxynucleotidyl transferase in diagnosis of lymphomas. Folia Haematol Int Mag Klin Morphol Blutforsch (1989) 0.75
[Native membrane immunoglobulins and immunoglobulins bound to B lymphocyte membranes]. Pol Arch Med Wewn (1984) 0.75
[Treatment of acute leukemias in adults. IV. Treatment results on 375 patients at 9 hematology centers]. Acta Haematol Pol (1982) 0.75
Diagnostic and prognostic value of the terminal deoxynucleotidyl transferase (TdT) activity in treating the blastic phase (bp) of chronic granulocytic leukaemia (CGL). Folia Haematol Int Mag Klin Morphol Blutforsch (1985) 0.75
[Terminal DNA nucleotidyltransferase in blastic crisis in myelocytic leukemia]. Acta Haematol Pol (1982) 0.75